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Preexisting 
Immunity to 
Pandemic (H1N1) 
2009 
To the Editor: The inﬂ  uenza A 
pandemic (H1N1) 2009 virus con-
tains a combination of 8 gene seg-
ments (1–3) antigenically similar to 
North American inﬂ  uenza  A  virus 
(H1N1) but different from seasonal 
human inﬂ   uenza A viruses (H1N1) 
(3). Despite the initial high number of 
deaths among patients in Mexico and 
among patients with speciﬁ  c  preex-
isting conditions, pandemic (H1N1) 
2009 virus in general has caused mild 
symptoms, and the overall death rate 
remains around 0.45% (www.who.int/
csr/don/2009_07_06/en).  Low viru-
lence of the virus and preexisting im-
mune status are among the main fac-
tors that account for lower death rates 
in inﬂ  uenza outbreaks. The Centers for 
Disease Control and Prevention (At-
lanta, GA, USA) reported that among 
persons >60 years old, 33% have pre-
existing, cross-reactive neutralizing 
antibodies against the new virus, but 
seasonal inﬂ   uenza vaccines do not 
elicit cross-reactive neutralizing anti-
bodies against pandemic (H1N1) 2009 
virus in either younger or older popula-
tions (1). However, current data cannot 
be used to evaluate the full immune ca-
pacities of human populations because 
cell-mediated immunity (CMI) has not 
been characterized in humans infected 
with pandemic (H1N1) 2009 virus. 
We performed a survey (4) for 
known human immune epitopes pres-
ent in the various proteins of seasonal 
inﬂ  uenza A virus strains and known 
to be efﬁ  cient in stimulating lympho-
cytes. We found that multiple major 
histocompatibility complex (MHC)–
restricted epitopes are conserved in 
nucleoprotein (NP) and matrix protein 
(MP), and even a few in the more vari-
able hemagglutinin (HA) protein, in A/
California/04/2009, A/Texas/04/2009, 
and A/New York/18/2009.  
For MHC class II antigen-re-
stricted epitopes essential for an-
tibody and Th1 responses, HA 
of pandemic (H1N1) 2009 virus 
contains HLA-DRA*0101/DRB1 
*0101-restricted SVIEKMNTQF-
TAV (5), as well as HLA-DRA*0101/
DRB1*0401-restricted EKMNTQF-
TAVGKE, TGLRNIPSIQSRG, and 
ELLVLLENERTLDY (5), and HLA-
DRB5*0101-restricted DYEELREQL
SSVSSFERFE (5) epitopes. These 
antigen-restricted epitopes were pres-
ent in globally-distributed seasonal 
H1N1 viruses, including classical A/
New Caledonia/20/1999 (H1N1) and 
A/Solomon Islands/3/2006 (H1N1). 
Overall, high levels of cross-reactive 
microneutralization (MN) or hemag-
glutination inhibition (HI) antibodies 
may not be detected against pandemic 
(H1N1) 2009 virus. This lack of detec-
tion of MN or HI antibodies is prob-
ably because most of these epitopes 
may not elicit MN/HI detectable anti-
bodies, or these epitopes may be pres-
ent in earlier seasonal inﬂ  uenza strains 
but not present in the current trivalent, 
inactivated inﬂ   uenza vaccine. Even 
though many do not contribute to neu-
tralizing antibodies, these MHC class 
II antigen-restricted epitopes may 
initiate the Th1 response, including 
activation of infected macrophages 
and antiviral cytokine production, and 
help host defenses as well.
For MHC class I antigen-restrict-
ed epitopes essential for CD8+ T cell 
activation and CMI, HA of pandemic 
(H1N1) 2009 virus contains HLA-
A*0201-restricted GLFGAIAGFI (6), 
which is present also in the HA of A/
New Caledonia/20/1999 (H1N1) and 
A/Solomon Islands/3/2006 (H1N1) 
viruses. More MHC class I antigen-
restricted epitopes in NP and MP of 
seasonal epidemic inﬂ  uenza  viruses 
(H1N1) and (H3N2) are conserved in 
pandemic (H1N1) virus. These sea-
sonal inﬂ  uenza viruses were isolated 
in North America, Europe, Africa, 
and Asia–Paciﬁ  c regions. Conserved 
epitopes in the HA and NP of pan-
demic (H1N1) 2009 virus are listed in 
the Table. In addition, ≈15 completely 
conserved epitopes are in the M pro-
tein of pandemic (H1N1) 2009 virus 
(data not shown).
Studies have demonstrated that 
both humoral and cell-mediated im-
mune responses may contribute to 
protection in inﬂ  uenza-vaccinated 
persons. As for humoral immunity, re-
sults have consistently indicated that 
serum HI or MN antibody titers cor-
relate inversely with morbidity rates 
after vaccination, which are the most 
valuable correlates of protection (7). 
Studies supporting the role of CMI in 
inﬂ  uenza viral clearance and host sur-
vival are well-documented in mouse 
models, but data are limited for hu-
mans. However, emerging evidence 
has demonstrated that either infection 
or vaccination can induce T cell-me-
diated immune responses in humans 
(8,9). Moreover, higher levels of 
CD8+ T cells correlate with reduced 
viral shedding among experimentally 
infected humans (10). Notably, among 
vaccinated persons >60 years of age, 
measures of the ex vivo cellular im-
mune response are statistically corre-
lated with protection against inﬂ  uenza 
illness but serum HI antibody levels 
are not, suggesting a role for CMI (9). 
Therefore, it is rational to expect that 
CMI does provide a protective role, 
and cross-reactive CMI to pandemic 
(H1N1) 2009 virus through conserved 
MHC class I-restricted epitopes may 
exist in persons previously vaccinated 
for or exposed to seasonal inﬂ  uenza.
We note that ≈80% of MHC 
class I epitopes in NP of seasonal and 
ﬂ   u vaccine viruses (Table) are also 
completely conserved in the highly 
pathogenic avian H5N1 virus (A/
Hong Kong/156/1997 and A/Hong 
Kong/97/1998) (www.ncbi.nlm.nih.
gov/genomes/FLU). Several points 
have to be made regarding the rel-
evance of these epitopes to its high as-
sociated mortality rate. First, inﬂ  uenza 
virus (H5N1) is known to be highly 
virulent, replicating at a much faster 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 11, November 2009  1847 LETTERS
pace than other inﬂ  uenza A viruses and 
spreading in vital organs shortly after 
infection and before epitope-mediated 
protective immunity can be launched, 
which may account for its high fa-
tality rate. Second, the epitopes are 
MHC class I antigen-restricted, which 
means that only a fraction of the hu-
man population will possess the cor-
rect MHC class I molecules capable of 
presenting a speciﬁ  c epitope and elic-
iting appropriate and protective CMI 
responses. This lack of correct MHC 
class I molecules could explain why 
patients of varied genetic backgrounds 
may have different prognoses upon in-
fection with pandemic (H1N1) 2009 
virus or even inﬂ  uenza virus (H5N1).
In fact, although there are no ex-
periments establishing a solid link, 
cross-reactive immunity from sea-
sonal inﬂ   uenz or vaccination may 
result in partial protection of patients 
infected with inﬂ  uenza virus (H5N1). 
As reported by WHO for inﬂ  uenza vi-
rus (H5N1)–infected patients, the inci-
dence of reported infections was lower 
for those >40 years of age (22/202, 
10.9%) than for those <39 years of age 
(180/202, 89.1%), and the fatality rate 
was 32% (7/22) for those >40 years of 
age and 59% (106/180) for those <40 
years of age from 2003 to 2006 (www.
who.int/wer/wer8126.pdf). Therefore, 
repeated exposure to seasonal inﬂ  u-
enza viruses or vaccination may have 
resulted in partial cell-mediated or 
humoral immunity to inﬂ  uenza virus 
(H5N1). The same type of immunity 
may have happened in persons ex-
posed to pandemic (H1N1) 2009 virus 
as well.
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Table. Conserved MHC class I antigen-restricted epitopes present in HA and NP 
proteins of pandemic (H1N1) 2009 virus* 
MHC antigen 
Epitope
position Sequence
Identified in selected 
virus isolates 
HA
 HLA-A*0201  344–353 GLFGAIAGFI  A/New  Caledonia/20/1999  (H1N1)
A/Solomon Islands/3/2006 (H1N1)
A/Macau/229/2008 (H1N1) 
A/Managua/254.01/2008(H1N1 
NP
 HLA-A1  44–52 CTELKLSDY  A/Hong  Kong/HKU4/2004  (H3N2) 
 HLA-A*0101  A/Canterbury/200/2004  (H3N2) 
 HLA-A3  265–273 ILRGSVAHK A/New  Caledonia/20/1999  (H1N1)
A/New York/55/2004 (H3N2) 
A/Managua/254.01/2008(H1N1) 
A/Taiwan/2645/2006 (H1N1) 
 HLA-B27  380–393 ELRSRYWAIRTRSG A/New  Caledonia/20/1999  (H1N1)
A/Taiwan/2645/2006 (H1N1) 
A/Managua/254.01/2008(H1N1) 
A/Florida/UR06-0383/2007(H1N1)
 HLA-B27  174–184 RRSGAAGAAVK  A/New  Caledonia/20/1999  (H1N1)
A/New York/55/2004 (H3N2) 
A/California/UR07-0067/2008 
(H3N2) 
A/Taiwan/2645/2006 (H1N1) 
 HLA-B*2705  357–370 KLSTRGVQIASNEN A/New  Caledonia/20/1999  (H1N1)
A/New York/55/2004 (H3N2) 
A/Hong Kong/HKU77/2005 
(H3N2) 
A/Managua/3153.01/2008 (H1N1)
 HLA-B*2705  383–391 SRYWAIRTR  A/New  Caledonia/20/1999 
A/Taiwan/2645/2006 (H1N1) 
A/Managua/4537.03/2008 (H1N1)
A/Florida/UR07-0026/2008 
(H1N1) 
 HLA-B*2702  381–388 LRSRYWAI  A/New  Caledonia/20/1999 
A/Florida/UR06-0383/2007(H1N1)
 HLA-B*4002  251–259 AEIEDLIFL A/Canterbury/200/2004  (H3N2) 
A/Hong Kong/HKU71/2005 
(H3N2) 
 HLA-B8  225–233 ILKGKFQTA  A/New  Caledonia/20/1999 
A/California/UR07-0067/2008 
(H3N2) 
A/Taiwan/2645/2006 (H1N1) 
 HLA-B8  380–388 ELRSRYWAI  A/New  Caledonia/20/1999  (H1N1)
 HLA-B*0801  A/Taiwan/2645/2006  (H1N1) 
A/Managua/107.01/2008 (H1N1) 
A/Florida/UR07-0026/2008 
(H1N1) 
*HA, hemagglutinin; NP, nucleoprotein; MHC, major histocompatibility complex; NA, neuraminidase. 
Epitope binding to and/or activation of specific lymphocytes prepared from human peripheral blood 
mononuclear cells (PBMC): MHC-tetramer staining; T-cell receptor binding; ELISPOT and 
intracellular cytokine staining (interferon Ȗ), and/or 
51Chromine release and killing have been 
demonstrated in published studies. Data on epitope characterization were collected from the 
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Serologic Survey 
of Pandemic 
(H1N1) 2009 Virus, 
Guangxi Province, 
China 
To the Editor: Since mid-April 
2009, a new inﬂ  uenza A virus (H1N1), 
now called  pandemic (H1N1) 2009 
virus, has caused inﬂ  uenza outbreaks 
in humans in North America (1) and 
a worldwide pandemic (2–4). Human 
pandemics occur when a new virus 
subtype emerges that is capable of 
human-to-human transmission in a 
population with little or no neutraliz-
ing antibodies to the new virus (4).
The current outbreak presents 
the  ﬁ   rst opportunity to directly ob-
serve this process. We used hemag-
glutination inhibition (HI) and virus 
neutralization (VN) assays to detect 
antibodies in 4,043 serum samples 
from residents (7–84 years of age) of 
2 counties in Guangxi Province, Peo-
ple’s Republic of China, collected dur-
ing July–August 2008. These persons 
were mostly farmers who lived in rural 
areas. Serum samples were obtained, 
transported, and frozen at –80°C as 
described (5). No participants had a 
history of vaccination against seasonal 
inﬂ  uenza. Antibodies were also detect-
ed in another 22 persons (<40 years of 
age) in Shantou, Guangdong Province, 
who had received 3 vaccinations for 
seasonal inﬂ  uenza since 2006.
Inﬂ  uenza viruses used in this study 
were A/California/04/2009 (H1N1; 
CA04), A/Brisbane/59/2007 (H1N1; 
B59), and A/swine/Hong Kong/915/
2004 (H1N2; Sw915). CA04 and B59 
were kindly provided by the World 
Health Organization Collaborating 
Centers for Reference and Research 
on Inﬂ  uenza (Atlanta, GA, USA, and 
Parkville, Victoria, Australia). Sw915 
was isolated from pigs by our labora-
tory. Seven of 8 genomic segments of 
Sw915 were located in a sister lineage 
to the current outbreak; this strain is 
the most closely related swine virus to 
CA04 identiﬁ  ed to date (6). All serum 
samples were treated with a receptor-
destroying enzyme and absorbed with 
fresh turkey erythrocytes to remove 
nonspeciﬁ   c inhibitors before the as-
says. All samples were tested by HI 
and VN assays according to standard 
protocols (5).
Screening by HI assay showed 
that 70 samples were positive (titers 
>40) for CA04 (Table). Examination 
by VN assay showed that of 70 HI-
positive serum samples, 12 had detect-
able neutralizing antibodies to CA04 
(positive rate 0.3%). Of these VN-pos-
itive samples, 10 had titers of 40–80 
and only 2 had neutralizing antibody 
titers >160 (Table). The 12 persons 
from whom the samples were obtained 
were 30–60 years of age. In contrast 
with ﬁ  ndings from a recent serologic 
survey of a US population (7), our re-
sults showed that none of the 583 per-
sons >60 years of age in our study was 
VN seropositive for CA04.
All 70 HI-positive samples for 
CA04 were also screened for neutral-
izing antibodies against Sw915. Thir-
teen samples collected from persons 
40–84 years of age were VN positive 
(titers 40–160). Of these 13 samples, 5 
were positive (VN titer >40) for CA04 
and 8 were negative. However, 7 CA04 
VN-positive samples were negative 
for Sw915. These ﬁ  ndings suggest that 
some cross-reactivity exists between 
CA04 and other Sw915-like H1 sub-
type viruses circulating in the pig popu-
lation in southern China, and that spo-
radic human infection with H1 swine 
viruses has occurred in rural China, 
where exposure to pigs is common.
In contrast, screening all 4,043 se-
rum samples with A/Brisbane/59/2007 
showed that 159 (3.9%) samples had 
HI titers >40, of which 116 (2.9%) 
had neutralizing antibodies (titer >40) 
(Table). Only 3 serum samples from 
persons >60 years of age were VN 
positive for B59. Because the study 
group was not vaccinated, these results 
likely reﬂ  ect natural infection rates for 
seasonal inﬂ  uenza virus (H1N1). The 
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